Major drug companies have issued statements in recent days assuring the public that their inventories are adequate in the face of supply chain threats stemming from the novel coronavirus Suppliers of active pharmaceutical ingredients (APIs) are also assuring customers that they are prepared for temporary interruption in the supply of key ingredients from firms in China, where the outbreak originated API makers in Europe and the US warn, however, that supply disruptions could result from a protracted delay in restarting production at plants closed in recent weeks by the Chinese government or from prolonged transportation restrictions James Bruno, president of the consulting firm Chemical and Pharmaceutical Solutions, says travel restrictions are already interrupting business with Chinese suppliers “First of all, nobody is going to be able to get to China,” he says, “so all the audits are going to be canceled ” Bruno adds that the restrictions will prolong plant closures